Premium
PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY‐FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK).
Author(s) -
Moccia A.,
Schär S.,
Hayoz S.,
Pirosa M.,
Taverna C.,
Novak U.,
Kimby E.,
Ghielmini M.,
Zucca E.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.73_2629
Subject(s) - medicine , rituximab , follicular lymphoma , oncology , randomized controlled trial , clinical trial , lymphoma , population , chemotherapy , clinical endpoint , progression free survival , environmental health